ClinicalTrials.gg
CompletedNCT00642954Updated Nov 18, 2020Results posted

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

A Phase 1 interventional study of Vorinostat and Lenalidomide in Relapsed or Refractory Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-18.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.

Enrollment
8th of 17
31 · median 31
Started
2008
with 4 others
Phase 1
10 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
6 of 19
Merck Sharp & Dohme LLC

Among the 19 studies testing vorinostat in Multiple Myeloma, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2008, is one of 10 in phase 1, and was the 6th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing vorinostat in Multiple Myeloma as a file.
02

Study summary

The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the incidence of dose-limiting toxicities (DLTs) and recommended Phase 2 dose (RP2D) as estimated by the incidence of drug-related adverse events (AEs).

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 31 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a male or female at least 18 years old
  • Has MM and has had at least one prior therapy
  • Female participants of must have 2 negative serum pregnancy tests prior to receiving the first dose of study drugs
  • Female participants who can become pregnant must agree to use 2 separate forms of effective at the same time, 4 weeks before, while taking, and for 4 weeks after stopping lenalidomide; post menopausal participants should be free from menses for >2 years, or are surgically sterilized
  • Male participant agrees to use an adequate method of contraception for the duration of the study, even if the participant has undergone a successful vasectomy
  • Male participants must agree to use a latex condom during sexual contact with a pregnant female or a female who can become pregnant; this is required for the duration of the study, and for 4 weeks after stopping therapy
  • Has at least 3 weeks prior to treatment
  • Is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis

Exclusion criteria

Exclusion Criteria:

  • Has prior treatment with a histone deacetylase (HDAC) inhibitor
  • Has prior allogenetic bone marrow transplant
  • Has received intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the start of the study drug
  • Uses illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
  • Is pregnant or breast feeding or expecting to have a baby during the course of the study
  • Has (HIV) infection
  • Has /C infection
  • Is currently receiving treatment for another type of cancer other than skin or cervical cancer that has not been in remission for 5 years or longer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Level 1: Vorinostat 300 mg + lenalidomide 10 mg

    Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.

    Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Level 2: Vorinostat 400 mg + lenalidomide 10 mg

    Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.

    Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Level 3: Vorinostat 400 mg + lenalidomide 15 mg

    Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.

    Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Level 4: Vorinostat 400 mg + lenalidomide 20 mg

    Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.

    Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Level 5: Vorinostat 400 mg + lenalidomide 25 mg

    Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.

    Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.

    Also known as: MK-0683, Suberoylanilide hydroxamic acid, Zolinza

  • Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.

    Also known as: Revlimid

  • Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.

    Also known as: Decadron

07

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)

    DLTs consisted of hematologic or non-hemtologic toxicities. Hematologic DLT was any grade (gr) 4 neutropenia lasting ≥7 days, gr 4 thrombocytopenia or gr 5 hematologic toxicity. Non-hematologic DLT was any gr 3, 4 or 5 non-hematologic toxicity with the exception of (1) gr 3 nausea, vomiting, diarrhea or dehydration not compliant with medical care, lasting \<48 hours (2) gr 3 acidosis/alkalosis returning to ≤ gr 2 by 48 hours of medical care (3) gr 3 liver function test elevation without symptoms, lasting ≤5 days (4) Gr 3 amylase elevation without symptoms (5) Gr 3 hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia or hyphosphatemia responding to medical care (6) Gr 3 hypercholeresterolemia or hypertriglyceridemia. A drug-related AE causing dose modification of study drug is also considered a DLT. Per protocol DLTs were analyzed in the first 28-day treatment cycle. The number of participants experiencing DLTs is reported here for all participants who got ≥1 dose of study drug.

    Time frame: Cycle 1 (Up to 28 days)

Secondary outcomes

  1. Number of Participants Experiencing Drug-Related Adverse Events (AEs)

    An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. An AE was considered related to a drug as determined by the investigator based on exposure (evidence of exposure to drug), time course (time of AE onset versus drug-induced effect), likely cause (AE etiology related or un-related to drug), de-challenge (drug dose reduction/discontinuation) or re-challenge (drug re-exposure). Per protocol participants experiencing drug-related AEs were analyzed at the time of the protocol-specified final statistical analysis with a 3-September (Sep)-2012 data cut-off. The number of participants experiencing drug-related AEs is reported here for all participants who got ≥1 dose of study drug.

    Time frame: Up to ~55 months (through pre-specified final statistical analysis cut-off date of 3-Sep-2012)

Other outcomes

  1. Number of Participants Experiencing Best Overall Response Determined by Complete Response (CR), Near Complete Response (NCR), Very Good Partial Response (VGPR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD) or Progressive Disease (PD)

    Best overall tumor response consisted of CR (negative M-protein immunofixation \[IF\], \<5% bone marrow \[BM\] plasma cells, no soft tissue plasmacytomas \[STP\]), NCR (positive M-protein IF, \<5% BM plasma cells, no STP), VGPR (≥90% M-protein decrease, \<5% BM plasma cells, no STP), PR (≥50% M-protein, BM plasma cells, STP decrease), MR (25-49% M-protein, BM plasma cells, STP decrease), SD (\<25% decrease-25% increase in M-protein, BM plasma cells; \<25% decrease-increase in definite STP) or PD (≥25% M-protein, BM plasma cells increase; new STP, lesions). Per protocol participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD were analyzed as a single prespecified analysis at the time of protocol-specified final statistical analysis with a 3-Sep-2012 data cut-off. The number of participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD is reported here for all participants who got ≥1 dose of study drug and had a post baseline efficacy assessment.

    Time frame: Up to ~55 months (through pre-specified final statistical analysis cut-off date of 3-Sep-2012)

08

Results

Posted Nov 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneLevel 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mg
Started443317
Completed00001
Not completed443316
Withdrew: Progressive disease33339
Withdrew: Withdrawal by subject00001
Withdrew: Adverse event11006

Outcome measures

PrimaryNumber of Participants Experiencing Dose-Limiting Toxicities (DLTs)

DLTs consisted of hematologic or non-hemtologic toxicities. Hematologic DLT was any grade (gr) 4 neutropenia lasting ≥7 days, gr 4 thrombocytopenia or gr 5 hematologic toxicity. Non-hematologic DLT was any gr 3, 4 or 5 non-hematologic toxicity with the exception of (1) gr 3 nausea, vomiting, diarrhea or dehydration not compliant with medical care, lasting \<48 hours (2) gr 3 acidosis/alkalosis returning to ≤ gr 2 by 48 hours of medical care (3) gr 3 liver function test elevation without symptoms, lasting ≤5 days (4) Gr 3 amylase elevation without symptoms (5) Gr 3 hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia or hyphosphatemia responding to medical care (6) Gr 3 hypercholeresterolemia or hypertriglyceridemia. A drug-related AE causing dose modification of study drug is also considered a DLT. Per protocol DLTs were analyzed in the first 28-day treatment cycle. The number of participants experiencing DLTs is reported here for all participants who got ≥1 dose of study drug.

Time frame:
Cycle 1 (Up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
ParticipantsLevel 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mg
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)00001
SecondaryNumber of Participants Experiencing Drug-Related Adverse Events (AEs)

An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. An AE was considered related to a drug as determined by the investigator based on exposure (evidence of exposure to drug), time course (time of AE onset versus drug-induced effect), likely cause (AE etiology related or un-related to drug), de-challenge (drug dose reduction/discontinuation) or re-challenge (drug re-exposure). Per protocol participants experiencing drug-related AEs were analyzed at the time of the protocol-specified final statistical analysis with a 3-September (Sep)-2012 data cut-off. The number of participants experiencing drug-related AEs is reported here for all participants who got ≥1 dose of study drug.

Time frame:
Up to ~55 months (through pre-specified final statistical analysis cut-off date of 3-Sep-2012)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Drug-Related Adverse Events (AEs)
ParticipantsLevel 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mg
Number of Participants Experiencing Drug-Related Adverse Events (AEs)233317
Other pre-specifiedNumber of Participants Experiencing Best Overall Response Determined by Complete Response (CR), Near Complete Response (NCR), Very Good Partial Response (VGPR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD) or Progressive Disease (PD)

Best overall tumor response consisted of CR (negative M-protein immunofixation \[IF\], \<5% bone marrow \[BM\] plasma cells, no soft tissue plasmacytomas \[STP\]), NCR (positive M-protein IF, \<5% BM plasma cells, no STP), VGPR (≥90% M-protein decrease, \<5% BM plasma cells, no STP), PR (≥50% M-protein, BM plasma cells, STP decrease), MR (25-49% M-protein, BM plasma cells, STP decrease), SD (\<25% decrease-25% increase in M-protein, BM plasma cells; \<25% decrease-increase in definite STP) or PD (≥25% M-protein, BM plasma cells increase; new STP, lesions). Per protocol participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD were analyzed as a single prespecified analysis at the time of protocol-specified final statistical analysis with a 3-Sep-2012 data cut-off. The number of participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD is reported here for all participants who got ≥1 dose of study drug and had a post baseline efficacy assessment.

Time frame:
Up to ~55 months (through pre-specified final statistical analysis cut-off date of 3-Sep-2012)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Best Overall Response Determined by Complete Response (CR), Near Complete Response (NCR), Very Good Partial Response (VGPR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD) or Progressive Disease (PD)
ParticipantsLevel 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mg
CR00001
NCR01000
VGPR10012
PR11015
MR00102
SD11105
PD11111

Adverse events

Collected over Up to ~66 months (through database cut-off date of 20-August-2013). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Level 1: Vorinostat 300 mg + Lenalidomide 10 mg0/4 (0%)2/4 (50%)4/4 (100%)
Level 2: Vorinostat 400 mg + Lenalidomide 10 mg1/4 (25%)1/4 (25%)4/4 (100%)
Level 3: Vorinostat 400 mg + Lenalidomide 15 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Level 4: Vorinostat 400 mg + Lenalidomide 20 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Level 5: Vorinostat 400 mg + Lenalidomide 25 mg3/17 (17.6%)8/17 (47.1%)17/17 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventLevel 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mg
DiarrhoeaGastrointestinal disorders0/40/40/31/31/17
Chest painGeneral disorders0/40/40/31/30/17
Accidental overdoseInjury, poisoning and procedural complications0/40/41/30/30/17
Sternal fractureInjury, poisoning and procedural complications0/40/40/31/30/17
Bronchitis viralInfections and infestations1/40/40/30/30/17
PneumoniaInfections and infestations1/41/40/30/32/17
SepsisInfections and infestations0/41/40/30/30/17
Septic shockInfections and infestations1/40/40/30/30/17
SyncopeNervous system disorders1/40/40/30/30/17
CoughRespiratory, thoracic and mediastinal disorders1/40/40/30/30/17
Most frequent other events
Showing 10 of 185
Most frequent other events
EventLevel 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mg
AnaemiaBlood and lymphatic system disorders4/41/41/33/39/17
Back painMusculoskeletal and connective tissue disorders1/40/43/30/35/17
DiarrhoeaGastrointestinal disorders2/43/42/31/37/17
Blood magnesium decreasedInvestigations3/40/41/32/32/17
Blood phosphorus decreasedInvestigations1/43/42/30/32/17
CoughRespiratory, thoracic and mediastinal disorders3/42/41/31/37/17
ThrombocytopeniaBlood and lymphatic system disorders2/42/41/31/312/17
NeutropeniaBlood and lymphatic system disorders2/42/41/32/36/17
DyspepsiaGastrointestinal disorders2/40/40/32/32/17
PyrexiaGeneral disorders0/42/42/30/34/17

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Level 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mgTotal
Mean69.5 ± 4.758.5 ± 2.166.3 ± 6.155.7 ± 2.564.1 ± 7.263.5 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)Level 1: Vorinostat 300 mg + Lenalidomide 10 mgLevel 2: Vorinostat 400 mg + Lenalidomide 10 mgLevel 3: Vorinostat 400 mg + Lenalidomide 15 mgLevel 4: Vorinostat 400 mg + Lenalidomide 20 mgLevel 5: Vorinostat 400 mg + Lenalidomide 25 mgTotal
Female2121713
Male23121018
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014 Feb 21;4(2):e182. doi: 10.1038/bcj.2014.1. Erratum In: Blood Cancer J. 2014 Apr 11;4:e202. doi: 10.1038/bcj.2014.23. PubMed 24562384 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2008 to primary completion in Sep 2012, 54 months.

Results were first posted in Nov 2020, 8 years 2 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 54 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2008
First posted
Mar 25, 2008
StartActual
Feb 13, 2008
Primary completionActual
Sep 3, 2012
CompletionActual
Aug 20, 2013
Results first posted
Nov 18, 2020
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00642954
Responsible party
Sponsor
First posted
Mar 25, 2008
Start date
Feb 13, 2008
Primary completion
Sep 3, 2012
Completion
Aug 20, 2013
Results posted
Nov 18, 2020
Last update
Nov 18, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vorinostat · Lenalidomide · Dexamethasone

Start the discussion